Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: A scoping review

Kate R Oppegaard; Terri S Armstrong; Joaquin A Anguera; Kord M Kober; Debra Lynch Kelly; Rob C Laister; Leorey N Saligan; Ana Patricia Ayala; John Kuruvilla; Mark W Alm; William H Byker; Christine Miaskowski; Samantha J Mayo

doi:10.1016/j.critrevonc.2022.103822

Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: A scoping review

Crit Rev Oncol Hematol. 2022 Dec:180:103822. doi: 10.1016/j.critrevonc.2022.103822. Epub 2022 Sep 21.

Authors

Affiliations

¹ University of California San Francisco, School of Nursing, Department of Physiological Nursing, USA.
² Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, USA.
³ University of California San Francisco, Department of Neurology and Psychiatry, USA.
⁴ University of Florida, College of Nursing, USA; University of Florida Health Cancer Center, USA.
⁵ Princess Margaret Cancer Centre, University Health Network, Canada.
⁶ Symptoms Biology Unit, Division of Intramural Research, National Institutes of Health, USA.
⁷ Gerstein Science Information Centre, University of Toronto, Canada.
⁸ Toronto General Hospital, University Health Network, Canada.
⁹ Vancouver General Hospital, Vancouver Coastal Health, Canada.
¹⁰ University of California San Francisco, School of Nursing, Department of Physiological Nursing, USA; University of California San Francisco, School of Medicine, Department of Anesthesia and Perioperative Care, USA.
¹¹ Princess Margaret Cancer Centre, University Health Network, Canada; Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Canada. Electronic address: samantha.mayo@utoronto.ca.

PMID: 36152911
DOI: 10.1016/j.critrevonc.2022.103822

Abstract

This scoping review was designed to synthesize the extant literature on associations between subjective and/or objective measures of cancer-related cognitive impairment (CRCI) and blood-based biomarkers in adults with non-central nervous system cancers. The literature search was done for studies published from the start of each database searched (i.e., MEDLINE, Embase, PsycINFO, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, grey literature) through to October 20, 2021. A total of 95 studies are included in this review. Of note, a wide variety of biomarkers were evaluated. Most studies evaluated patients with breast cancer. A variety of cognitive assessment measures were used. The most consistent significant findings were with various subjective and objective measures of CRCI and levels of interleukin-6 and tumor necrosis factor. Overall, biomarker research is in an exploratory phase. However, this review synthesizes findings and proposes directions for future research.

Keywords: Biomarkers; Cancer; Cancer-related cognitive impairment; Chemotherapy-related cognitive impairment; Cytokines; Scoping review.

Publication types

Review

MeSH terms

Adult
Biomarkers
Breast Neoplasms*
Cognitive Dysfunction* / diagnosis
Cognitive Dysfunction* / etiology
Female
Humans
Nervous System

Substances

Biomarkers

Grants and funding

T32 NR016920/NR/NINR NIH HHS/United States